CD133 as a marker for regulation and potential for targeted therapies in glioblastoma Multiforme

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 391-405

  Choy, Winward ^a   Nagasawa, Daniel T ^a   Trang, Andy ^a   Thill, Kimberly ^a   Spasic, Marko ^a   Yang, Isaac ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cell; CD133; Glioblastoma; Glioma

Indexed keywords

CD133 ANTIGEN; EPITOPE; TUMOR MARKER;

CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RESISTANCE; CANCER STEM CELL; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL ISOLATION; CELL PROLIFERATION; DISEASE MARKER; DRUG TARGETING; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW;

ANIMALS; ANTIGENS, CD; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; MICE; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84862995339     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.011     Document Type: Review

References (130)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Holland E.C. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000, 97:6242-6244.
3. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
4. Dirks P.B. Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci 2008, 363:139-152.
5. Yin A.H., Miraglia S., Zanjani E.D., et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
6. Mizrak D., Brittan M., Alison M.R. CD133: molecule of the moment. J Pathol 2008, 214:3-9.
7. Wan F., Zhang S., Xie R., et al. The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 2010, 20:877-889.
8. Bidlingmaier S., Zhu X., Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) 2008, 86:1025-1032.
9. Shmelkov S.V., St Clair R., Lyden D., et al. AC133/CD133/Prominin-1. Int J Biochem Cell Biol 2005, 37:715-719.
10. Miraglia S., Godfrey W., Yin A.H., et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
11. Corbeil D., Roper K., Fargeas C.A., et al. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2:82-91.
12. Maw M.A., Corbeil D., Koch J., et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000, 9:27-34.
13. Zacchigna S., Oh H., Wilsch-Brauninger M., et al. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J Neurosci 2009, 29:2297-2308.
14. Barcelos L.S., Duplaa C., Krankel N., et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ Res 2009, 104:1095-1102.
15. Ji J., Black K.L., Yu J.S. Glioma stem cell research for the development of immunotherapy. Neurosurg Clin N Am 2010, 21:159-166.
16. Campos B., Herold-Mende C.C. Insight into the complex regulation of CD133 in glioma. Int J Cancer 2011, 128:501-510.
17. Uchida N., Buck D.W., He D., et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000, 97:14720-14725.
18. Tamaki S., Eckert K., He D., et al. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J Neurosci Res 2002, 69:976-986.
19. Schwartz P.H., Bryant P.J., Fuja T.J., et al. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003, 74:838-851.
20. Belicchi M., Pisati F., Lopa R., et al. Human skin-derived stem cells migrate throughout forebrain and differentiate into astrocytes after injection into adult mouse brain. J Neurosci Res 2004, 77:475-486.
21. Hao H.N., Zhao J., Thomas R.L., et al. Fetal human hematopoietic stem cells can differentiate sequentially into neural stem cells and then astrocytes in vitro. J Hematother Stem Cell Res 2003, 12:23-32.
22. Peichev M., Naiyer A.J., Pereira D., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
23. Corbeil D., Roper K., Hellwig A., et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000, 275:5512-5520.
24. Richardson G.D., Robson C.N., Lang S.H., et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004, 117:3539-3545.
25. Leong K.G., Wang B.E., Johnson L., et al. Generation of a prostate from a single adult stem cell. Nature 2008, 456:804-808.
26. Cheng J.X., Liu B.L., Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors?. Cancer Treat Rev 2009, 35:403-408.
27. Tirino V., Desiderio V., d'Aquino R., et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008, 3:e3469.
28. Zhou L., Wei X., Cheng L., et al. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007, 117:455-460.
29. Frank N.Y., Margaryan A., Huang Y., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005, 65:4320-4333.
30. Frank N.Y., Pendse S.S., Lapchak P.H., et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 2003, 278:47156-47165.
31. Klein W.M., Wu B.P., Zhao S., et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007, 20:102-107.
32. Monzani E., Facchetti F., Galmozzi E., et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007, 43:935-946.
33. Wright M.H., Calcagno A.M., Salcido C.D., et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10:R10.
34. Suetsugu A., Nagaki M., Aoki H., et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006, 351:820-824.
35. Collins A.T., Berry P.A., Hyde C., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
36. Miki J., Furusato B., Li H., et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007, 67:3153-3161.
37. Shmelkov S.V., Jun L., St Clair R., et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004, 103:2055-2061.
38. Kratz-Albers K., Zuhlsdorp M., Leo R., et al. Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. Blood 1998, 92:4485-4487.
39. Buhring H.J., Seiffert M., Marxer A., et al. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34 + B-cell precursors. Blood 1999, 94:832-833.
40. Tirino V., Camerlingo R., Franco R., et al. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009, 36:446-453.
41. Taylor M.D., Poppleton H., Fuller C., et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005, 8:323-335.
42. Vescovi A.L., Galli R., Reynolds B.A. Brain tumour stem cells. Nat Rev Cancer 2006, 6:425-436.
43. Ignatova T.N., Kukekov V.G., Laywell E.D., et al. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002, 39:193-206.
44. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
45. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
46. Houchens D.P., Ovejera A.A., Riblet S.M., et al. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 1983, 19:799-805.
47. Hu B., Guo P., Fang Q., et al. Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 2003, 100:8904-8909.
48. Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64:7011-7021.
49. Yuan X., Curtin J., Xiong Y., et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23:9392-9400.
50. Zeppernick F., Ahmadi R., Campos B., et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008, 14:123-129.
51. Clément V., Dutoit V., Marino D., et al. Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer 2009, 125:244-248.
52. Joo K.M., Kim S.Y., Jin X., et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008, 88:808-815.
53. Shu Q., Wong K.K., Su J.M., et al. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells 2008, 26:1414-1424.
54. Wang J., Sakariassen P.O., Tsinkalovsky O., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008, 122:761-768.
55. Yan X., Ma L., Yi D., et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A 2011, 108:1591-1596.
56. Bao S., Wu Q., Sathornsumetee S., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006, 66:7843-7848.
57. Beier D., Hau P., Proescholdt M., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007, 67:4010-4015.
58. Son M.J., Woolard K., Nam D.H., et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
59. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004, 101:781-786.
60. Wu A., Oh S., Wiesner S.M., et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008, 17:173-184.
61. Broadley K.W., Hunn M.K., Farrand K.J., et al. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem Cells 2011, 29:452-461.
62. Lathia J.D., Gallagher J., Heddleston J.M., et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432.
63. Ogden A.T., Waziri A.E., Lochhead R.A., et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008, 62:505-514. [discussion: 514-5].
64. Tabatabai G., Weller M. Glioblastoma stem cells. Cell Tissue Res 2011, 343:459-465.
65. Gunther H.S., Schmidt N.O., Phillips H.S., et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008, 27:2897-2909.
66. Rasper M., Schafer A., Piontek G., et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro Oncol 2010, 12:1024-1033.
67. Fatoo A., Nanaszko M.J., Allen B.B., et al. Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. J Neurooncol 2011, 103:397-408.
68. Zheng X., Shen G., Yang X., et al. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007, 67:3691-3697.
69. Lee J., Kotliarova S., Kotliarov Y., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
70. Fargeas C.A., Joester A., Missol-Kolka E., et al. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci 2004, 117:4301-4311.
71. Osmond T.L., Broadley K.W., McConnell M.J. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein. Int J Mol Med 2010, 25:883-888.
72. Florek M., Haase M., Marzesco A.M., et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005, 319:15-26.
73. Shackleton M., Quintana E., Fearon E.R., et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
74. Lottaz C., Beier D., Meyer K., et al. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010, 70:2030-2040.
75. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
76. Chen R., Nishimura M.C., Bumbaca S.M., et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
77. Dai C., Celestino J.C., Okada Y., et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001, 15:1913-1925.
78. Read T.A., Fogarty M.P., Markant S.L., et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15:135-147.
79. Schuller U., Heine V.M., Mao J., et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008, 14:123-134.
80. Uhrbom L., Dai C., Celestino J.C., et al. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002, 62:5551-5558.
81. Yang Z.J., Ellis T., Markant S.L., et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008, 14:135-145.
82. Engebraaten O., Hjortland G.O., Hirschberg H., et al. Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 1999, 90:125-132.
83. Kaloshi G., Mokhtari K., Carpentier C., et al. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol 2007, 84:245-248.
84. Liang Y., Bollen A.W., Aldape K.D., et al. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 2006, 6:97.
85. Arai Y., Funatsu N., Numayama-Tsuruta K., et al. Role of Fabp7, a downstream gene of Pax6, in the maintenance of neuroepithelial cells during early embryonic development of the rat cortex. J Neurosci 2005, 25:9752-9761.
86. McCord A.M., Jamal M., Shankavaram U.T., et al. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 2009, 7:489-497.
87. Pouyssegur J., Dayan F., Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437-443.
88. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
89. Evans S.M., Judy K.D., Dunphy I., et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004, 10:8177-8184.
90. Dings J., Meixensberger J., Jager A., et al. Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. Neurosurgery 1998, 43:1082-1095.
91. Platet N., Liu S.Y., Atifi M.E., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007, 258:286-290.
92. Griguer C.E., Oliva C.R., Gobin E., et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008, 3:e3655.
93. Li Z., Wang H., Eyler C.E., et al. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem 2009, 284:16705-16709.
94. Matsumoto K., Arao T., Tanaka K., et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009, 69:7160-7164.
95. Forristal C.E., Wright K.L., Hanley N.A., et al. Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 2010, 139:85-97.
96. Tabu K., Sasai K., Kimura T., et al. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008, 18:1037-1046.
97. Yi J.M., Tsai H.C., Glockner S.C., et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008, 68:8094-8103.
98. Jaksch M., Munera J., Bajpai R., et al. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008, 68:7882-7886.
99. Gray D., Jubb A.M., Hogue D., et al. Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res 2005, 65:9751-9761.
100. El Hallani S., Boisselier B., Peglion F., et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010, 133:973-982.
101. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740-745.
102. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
103. Soda Y., Marumoto T., Friedmann-Morvinski D., et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 2011, 108:4274-4280.
104. He H., Niu C.S., Li M.W. Correlation between glioblastoma stem-like cells and tumor vascularization. Oncol Rep 2012, 27:45-50.
105. Wang R., Chadalavada K., Wilshire J., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
106. Ricci-Vitiani L., Pallini R., Biffoni M., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
107. Marumoto T., Tashiro A., Friedmann-Morvinski D., et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009, 15:110-116.
108. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
109. Bertolini F., Shaked Y., Mancuso P., et al. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6:835-845.
110. Gunsilius E., Duba H.C., Petzer A.L., et al. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet 2000, 355:1688-1691.
111. Streubel B., Chott A., Huber D., et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004, 351:250-259.
112. Rigolin G.M., Fraulini C., Ciccone M., et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006, 107:2531-2535.
113. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
114. Fuchs E., Tumbar T., Guasch G. Socializing with the neighbors: stem cells and their niche. Cell 2004, 116:769-778.
115. Moore K.A., Lemischka I.R. Stem cells and their niches. Science 2006, 311:1880-1885.
116. Borovski T., De Sousa E.M.F., Vermeulen L., et al. Cancer stem cell niche: the place to be. Cancer Res 2011, 71:634-639.
117. Shen Q., Goderie S.K., Jin L., et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 2004, 304:1338-1340.
118. Ramirez-Castillejo C., Sanchez-Sanchez F., Andreu-Agullo C., et al. Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat Neurosci 2006, 9:331-339.
119. Leventhal C., Rafii S., Rafii D., et al. Endothelial trophic support of neuronal production and recruitment from the adult mammalian subependyma. Mol Cell Neurosci 1999, 13:450-464.
120. Louissaint A., Rao S., Leventhal C., et al. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 2002, 34:945-960.
121. He H., Li M.W., Niu C.S. The pathological characteristics of glioma stem cell niches. J Clin Neurosci 2012, 19(1):121-127.
122. Charles N., Holland E.C. The perivascular niche microenvironment in brain tumor progression. Cell Cycle 2010, 9:3012-3021.
123. Pallini R., Ricci-Vitiani L., Banna G.L., et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008, 14:8205-8212.
124. Beier D., Wischhusen J., Dietmaier W., et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008, 18:370-377.
125. Kong D.S., Kim M.H., Park W.Y., et al. The progression of gliomas is associated with cancer stem cell phenotype. Oncology Reports 2008, 19:639-643.
126. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
127. Angelastro J.M., Lame M.W. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 2010, 8:1105-1115.
128. Salmaggi A., Boiardi A., Gelati M., et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006, 54:850-860.
129. Liu G., Yuan X., Zeng Z., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:67.
130. Das S., Srikanth M., Kessler J.A. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008, 4:427-435.